Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis

Original Article

J.S. Smolen, E. Feist, S. Fatenejad, S.A. Grishin, E.V. Korneva, E.L. Nasonov, M.Y. Samsonov, and R.M. Fleischmann

N Engl J Med 2022;387:715-726

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
08/24/2022
Course expires: 
08/25/2024
Take course

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Take course